España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
PharmaTher Holdings
PHRRF
OTCQB
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.1528
0.00390
2.62%
At close: -
Get Report
Comment
PharmaTher Holdings (PHRRF) Forecast
News
Earnings
PharmaTher Holdings (PHRRF) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for PharmaTher Holdings (OTC:PHRRF) Stock
PharmaTher Holdings Stock (OTC: PHRRF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, January 15, 2024
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
Lara Goldstein
Monday, October 02, 2023
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
Lara Goldstein
Wednesday, September 27, 2023
PharmaTher Is 'One Step Closer To Being A Ketamine Leader' Due To FDA Acceptance
Lara Goldstein
Tuesday, September 12, 2023
Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years, NY Consulting Firm Predicts
Lara Goldstein
Monday, September 11, 2023
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Lara Goldstein
Wednesday, September 06, 2023
PharmaTher Aims To Mitigate Ketamine Shortage With New FDA Application
Lara Goldstein
Monday, July 24, 2023
Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More
Lara Goldstein
Tuesday, July 18, 2023
PharmaTher's DMT Patch Shows Positive Outcomes, Investment Toward The Clinical Stage
Lara Goldstein
Tuesday, July 04, 2023
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
Lara Goldstein
Wednesday, June 28, 2023
BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives
Lara Goldstein
Tuesday, June 27, 2023
Ketamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip Assets
Lara Goldstein
Wednesday, June 21, 2023
PharmaTher's Novel Ketamine Heads For The US Market With New Collaboration Agreement
Lara Goldstein
Monday, May 08, 2023
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
Lara Goldstein
Wednesday, May 03, 2023
Parkinson's Patients May Benefit From Ketamine, PharmaTher Applies For FDA Fast Track
Nicolás Jose Rodriguez
Wednesday, April 05, 2023
Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More
Lara Goldstein
Monday, April 03, 2023
MDMA Transdermal Patch Moves Toward First-In-Human Trials: Latest Development Update
Lara Goldstein
Thursday, March 30, 2023
Ketamine Company Advances Parkinson's Treatment Through Final Stages Toward FDA Approval
Lara Goldstein
Tuesday, February 28, 2023
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Lara Goldstein
Wednesday, February 22, 2023
Development Of DMT Transdermal Patch With Eye Disease Treatment In Mind
Lara Goldstein
Monday, February 13, 2023
Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More
Lara Goldstein
Tuesday, February 07, 2023
PharmaTher Seeks Regulatory Approval Of New Ketamine Delivery System For Anesthesia And Sedation
Lara Goldstein
Monday, February 06, 2023
Psyched: Australia Legalizes Psychedelics Therapy, BC's Decrim, State Bills, Millions For Trials & Clinics
Lara Goldstein
MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations
Lara Goldstein
Friday, February 03, 2023
PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch
Lara Goldstein
Wednesday, January 25, 2023
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
Lara Goldstein
Saturday, January 21, 2023
Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News
Lara Goldstein
Thursday, January 19, 2023
Psychedelics Market Could Reach $12B By 2029, Says New Report
Lara Goldstein
Wednesday, January 11, 2023
2 Psychedelics Companies Tout Advanced Clinical Trials, Progress With Key Products
Lara Goldstein
Thursday, December 15, 2022
FDA OKs Ketamine For Treating Organ Transplant Injuries With 'Orphan Drug' Status
Lara Goldstein
Tuesday, November 01, 2022
Ketamine Could Soon Be A Treatment Option For This Rare Genetic Neurological Disorder
Lara Goldstein
Wednesday, October 05, 2022
Ketamine for Parkinson's Disease, PharmaTher Holdings Announces Grant of U.S. Patent To Cover It
Joana Scopel
Thursday, September 29, 2022
PharmaTher Provides Business Highlights And Releases Audited Annual Financials
Lara Goldstein
Saturday, September 17, 2022
PharmaTher Presents Positive Data On Ketamine For Treatment Of Dyskinesia In Parkinson's Disease
Nicolás Jose Rodriguez
Wednesday, September 07, 2022
Intradermal Ketamine Patch Completes Pre-Clinical Phase, Advances To Clinical Studies
Lara Goldstein
Wednesday, July 13, 2022
PharmaTher Receives Notice Of Allowance For U.S. Patent Covering Ketamine For Parkinson's And Motor Disorders Treatment
Lara Goldstein
Wednesday, June 29, 2022
PharmaTher's Preclinical Trial For Ketamine Micro-Needle Patch Shows Positive Results For Dosing
Lara Goldstein
Thursday, June 02, 2022
These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry
Natan Ponieman
Thursday, May 26, 2022
More Synergies On The Go: New Wearable Ketamine Delivery Device by PharmaTher & CCBIO
Lara Goldstein
Tuesday, May 10, 2022
Psyched: Protesters At DEA HQ Demand Access To Psychedelics, Connecticut Approves Budget Bill With MDMA & Psilocybin Programs
Natan Ponieman
Thursday, May 05, 2022
Pharmather Lands US Patent To Formulate, Produce Ketamine With This New Process
Fermin Orgambide
Monday, May 02, 2022
Psyched: Elon Musk Praises Psychedelics Over Antidepressants, Field Trip To Split In Two, Colorado MDMA Bill Moves Forward
Natan Ponieman
Tuesday, April 26, 2022
Pharmather Reports Improved Q3 Results, Continues Ketamine Trials For Epilepsy
Fermin Orgambide
Thursday, March 24, 2022
Ketamine Could Help Treat Parkinson's Disease...
Benzinga Newsdesk
Tuesday, January 25, 2022
Psychedelic Medicine Co. PharmaTher Provides Update On Pipeline And Milestones For 2022
Microdose Psychedelic Insights
Wednesday, January 12, 2022
FDA Approves PharmaTher's Phase 2 Trial For Ketamine ALS Treatment
Aaron Bry
Monday, November 08, 2021
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
Natan Ponieman
Monday, October 18, 2021
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Natan Ponieman
A Look At PharmaTher And Its Recent Bull Run: Where's The Psychedelics Stock Headed?
Microdose Psychedelic Insights
Wednesday, October 13, 2021
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Natan Ponieman
Monday, October 11, 2021
Psyched: Seattle Decriminalizes Psychedelics, Psilocybin Increases Emotions From Music, Novamind's Palliative Care Program
Natan Ponieman
Show More
